Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

MAIA Biotechnology, Inc. MAIA NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
1/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

MAIA Biotechnology, Inc. (MAIA) is a Biotechnology company in the Healthcare sector, currently trading at $1.42. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 1 out of 7 criteria passed.

Valuation: MAIA trades at a trailing Price-to-Earnings (P/E) of -1.7 (S&P 500 average ~25).

Net income is $22M (loss), growing at -13%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $2M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 1.66 (strong liquidity). Debt-to-assets is 0%. Total assets: $10M.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

MAIA SharesGrow Score Overview

48/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — MAIA

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
MAIA: +0%/yr revenue is, -13%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet MAIA: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 1.66 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
MAIA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.87-3.19
Volume772.18K
Avg Volume (30D)1.12M
Market Cap$54.9M
Beta (1Y)0.32
Share Statistics
EPS (TTM)-0.70
Shares Outstanding$32.12M
IPO Date2022-07-28
Employees13
CEOVlad Vitoc
Financial Highlights & Ratios
EBITDA$-24.27M
Net Income$-22.4M
Operating Income$-24.27M
Total Cash$8.66B
Net Debt$-8.66B
Total Assets$9.7M
Price / Earnings (P/E)-2
Analyst Forecast
Company Info
CountryUS
ExchangeNYSE
CurrencyUSD
ISINUS5526411021

Price Chart

Track all markets on TradingView
MAIA
MAIA Biotechnology, Inc. ↗  ·  NYSE
Healthcare • Biotechnology
0.87 52WK RANGE 3.19

People Also View

TLPPF
TLPPF
Telix Pharmaceuticals Limited
$10.50
-2.78%
 ROIVW
ROIVW
Roivant Sciences Ltd.
$2.75
+4.56%
 ARMP
ARMP
Armata Pharmaceuticals, Inc.
$12.06
-6.37%
 LRMR
LRMR
Larimar Therapeutics, Inc.
$4.83
-0.82%
 NAUT
NAUT
Nautilus Biotechnology, Inc.
$3.25
+6.21%
 LCTX
LCTX
Lineage Cell Therapeutics, Inc.
$1.63
+2.52%
 MNPR
MNPR
Monopar Therapeutics Inc.
$57.91
-0.02%
 GRPH
GRPH
Graphite Bio, Inc.
$3.18
-2.75%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message